| Tri-county Dental, Pc | |
|
104 Memorial Dr Gowanda NY 14070-1111 | |
| (716) 532-4022 | |
| (716) 532-2428 |
| Full Name | Tri-county Dental, Pc |
|---|---|
| Speciality | Dentist - General Practice |
| Location | 104 Memorial Dr, Gowanda, New York |
| Authorized Official Name and Position | Tracy Culver (DIRECTOR) |
| Authorized Official Contact | 7165324022 |
| Accepts Medicare Insurance | This clinic does not participate in Medicare Program. |
| Mailing Address | Practice Location Address |
|---|---|
| Tri-county Dental, Pc 104 Memorial Dr Gowanda NY 14070-1111 Ph: (716) 532-4022 | Tri-county Dental, Pc 104 Memorial Dr Gowanda NY 14070-1111 Ph: (716) 532-4022 |
| NPI Number | 1578687216 |
|---|---|
| Provider Enumeration Date | 03/19/2007 |
| Last Update Date | 08/22/2020 |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1578687216 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1223G0001X | Dentist - General Practice | (* (Not Available)) | Primary |
News Archive
Fecal color and consistency are well-known markers of digestive health in both children and adults, but paying attention to a newborn's shade of poop can be a decided lifesaver in babies born with the rare, liver-ravaging disorder biliary atresia, commonly heralded by white or clay-colored stool.
People who smoke are more likely to develop Alzheimer's disease or dementia than nonsmokers or those who smoked in the past, according to a study published in the September 4, 2007, issue of Neurology, the medical journal of the American Academy of Neurology.
People who walk to work are around 40 per cent less likely to have diabetes as those who drive, according to a new study.
Bioethicists at the Johns Hopkins Berman Institute of Bioethics are co-authors on a consensus article placing "significant responsibility" on biobanks to report individual research results (IRRs) and incidental findings (IFs) to the contributors of genetic material.
Cerulean Pharma Inc., a leader in designing and developing nanopharmaceuticals, today announced that results of a Phase 1 clinical study of CRLX101 (formerly IT-101), Cerulean's lead clinical development candidate, and pre-clinical data on Cerulean's development candidate, CRLX288, were presented at the American Chemical Society National Meeting & Exposition, ongoing in Boston, Massachusetts.
› Verified 2 days ago